Tirzepatide vs. Semaglutide: A Clinical Comparison for Prescribers
Both are GLP's receptor agonists, but tirzepatide adds GIP agonism — and the clinical data shows a meaningful difference in outcomes. Here is what prescribers need to know when choosing between them.
Tirzepatide vs. Semaglutide: A Clinical Comparison for Prescribers
When a patient presents for GLP-1 therapy, the first clinical decision is which molecule to prescribe. Semaglutide and tirzepatide are both approved for type 2 diabetes and obesity, both available as compounded versions through 503A/503B channels, and both widely used in outpatient weight management programs. But they are not interchangeable.
This comparison is designed for licensed prescribers who need a clear, evidence-based framework for choosing between them.
Mechanism of Action: The Core Difference
Semaglutide is a selective GLP-1 receptor agonist. It mimics the action of endogenous GLP-1, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system pathways.
Tirzepatide is a dual GLP-1/GIP receptor agonist — often called a "twincretin." It activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. The GIP component appears to enhance the metabolic effects of GLP-1 agonism, particularly in adipose tissue, and may reduce some of the GI side effects associated with pure GLP-1 agonism.
The dual mechanism is not just additive — the interaction between GLP-1 and GIP signaling appears to produce synergistic effects on weight loss and glycemic control.
Efficacy Data: Head-to-Head Outcomes
Weight Loss
The SURMOUNT trials for tirzepatide and the STEP trials for semaglutide provide the most relevant comparison data, though they were not head-to-head studies.
| Metric | Semaglutide 2.4mg (STEP 1) | Tirzepatide 15mg (SURMOUNT-1) |
|---|---|---|
| Mean weight loss | 14.9% body weight | 20.9% body weight |
| ≥15% weight loss | 32% of participants | 57% of participants |
| ≥20% weight loss | 12% of participants | 36% of participants |
The SURMOUNT-5 trial, which directly compared tirzepatide 10mg and 15mg against semaglutide 2.4mg, showed tirzepatide produced approximately 47% greater weight loss at 72 weeks.
Glycemic Control
Both agents produce significant HbA1c reductions in type 2 diabetes. Tirzepatide shows a modest advantage in HbA1c reduction in head-to-head trials, likely due to the GIP component's enhancement of insulin secretion.
Cardiovascular Outcomes
Semaglutide has robust MACE data from the SUSTAIN-6 and SELECT trials. Tirzepatide's cardiovascular outcomes data (SURPASS-CVOT) is more recent and shows comparable MACE reduction. For patients with established cardiovascular disease, semaglutide currently has a longer evidence track record.
Side Effect Profile
Both agents share the GLP-1 class side effects: nausea, vomiting, diarrhea, and constipation, particularly during dose titration. The dual GIP mechanism in tirzepatide appears to modestly reduce nausea compared to semaglutide at equivalent efficacy doses, though individual variation is significant.
Practical titration note: Both compounds require slow titration to minimize GI side effects. Patients who discontinue due to nausea on semaglutide may tolerate tirzepatide better — and vice versa. Having both available in your practice gives you a meaningful clinical tool.
Compounded Availability and Supply Considerations
Both semaglutide and tirzepatide are available as compounded versions through 503A and 503B channels, subject to current FDA shortage designations.
Tirzepatide has maintained a more consistent shortage designation through 2026, making it a more supply-stable option for practices building a GLP-1 program.
Semaglutide shortage status has fluctuated more, with the FDA updating designations at specific dosage strengths. Practices relying solely on compounded semaglutide have experienced more supply uncertainty.
A well-structured GLP-1 practice carries both molecules and can switch patients based on clinical response, tolerance, and supply availability.
Patient Selection Framework
| Patient Profile | Preferred Starting Agent |
|---|---|
| Maximum weight loss priority | Tirzepatide |
| Established cardiovascular disease | Semaglutide (more MACE data) |
| GI intolerance to semaglutide | Trial tirzepatide |
| Type 2 diabetes + obesity | Either; tirzepatide shows modest HbA1c advantage |
| Cost-sensitive (compounded) | Both comparable; check current shortage status |
| Prior GLP-1 non-responder | Consider retatrutide (IRB program) |
Dosing Reference
Semaglutide (compounded, subcutaneous):
- Start: 0.25mg weekly × 4 weeks
- Titrate: 0.5mg → 1mg → 1.7mg → 2.4mg at 4-week intervals
- Maintenance: 1.7–2.4mg weekly
Tirzepatide (compounded, subcutaneous):
- Start: 2.5mg weekly × 4 weeks
- Titrate: 5mg → 7.5mg → 10mg → 12.5mg → 15mg at 4-week intervals
- Maintenance: 5–15mg weekly based on response and tolerance
The Bottom Line
For most patients presenting for weight management, tirzepatide offers superior weight loss outcomes based on current trial data. For patients with established cardiovascular disease or those who have previously responded well to semaglutide, semaglutide remains an excellent choice.
The most effective GLP-1 practices carry both molecules, titrate carefully, and switch based on individual response rather than defaulting to one agent for all patients.
MedClinic Partners provides compounded tirzepatide and semaglutide through verified 503A and 503B facilities with next-day refrigerated delivery. NPI-verified portal access is available same-day for licensed providers.
Explore Topics
Written by
MedClinic Partners Editorial Team
B2B Medical Supply & Compounding Experts
The MedClinic Partners editorial team is composed of licensed medical operators, compounding compliance specialists, and mass-tort attorneys with direct experience running GLP-1 and peptide programs across all 50 states. Every article is reviewed for clinical accuracy, regulatory compliance, and practical applicability before publication.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
